2016-03-12T00:00:00.000-05:00
debilitating genetic diseases,-0.61151
clinical-stage biopharmaceutical company,0.292876
earnings results,-0.204363
strong buy rating,0.419497
Russell Frank,0.47617
price target,0.264795
stock,-0.00551614
Pharmaceutical Inc Daily,0.385693
Capital Partners LLP,0.249269
InvestorPlace Broker Center,0.555736
MarketBeat Ratings reports,-0.201529
research report,0.257516
biopharmaceutical company,0.324387
Paradigm Asset Management,0.281308
personal trading style,0.598412
Tocqueville Asset Management,0.289511
Stifel Nicolaus,0.250236
GSA Capital Partners,0.249269
JPMorgan Chase,0.278876
average price,-0.235316
consensus estimate,-0.453801
shares,0.0999959
concise daily summary,0.502738
Asset Management L.P.,0.289511
consensus target price,0.489286
stock broker,0.245696
consensus rating,0.526131
Asset Management,0.284042
Ultragenyx Pharmaceutical,0.373282
quarter,0.338317
